Company: HCTI
Filing Date: 2025-11-19
Form Type: 424B5
Source: 0001213900-25-112544
Chunk: 17

Company: Healthcare Triangle, Inc.
Filing Date: 2025-11-19
Form: 424B5
Chunk 17
---
 that will be sold
or the gross proceeds we will raise in connection with those sales.

Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.

Sales of a significant number of shares of our
common stock in the public markets, or the perception that such sales could occur as a result of our utilization of our shelf registration
statement, our ATM Sales Agreement with the Sales Agent or otherwise could depress the market price of our common stock and impair our
ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common
stock or the market perception that we are permitted to sell a significant number of our securities would have on the market price of
our common stock.

<div align='center'>S-7

USE OF PROCEEDS</div>

We may offer and sell shares of our common stock
having aggregate sales proceeds of up to $20,000,000 from time to time, before deducting the commissions and estimated offering expenses
payable by us. However, we cannot guarantee if or when these net proceeds, if any, will be received. The amount of proceeds from this
offering will depend upon the number of shares of our common stock sold, if any, and the market price at which they are sold. There can
be no assurance that we will be able to sell any shares under or fully utilize the ATM Sales Agreement with the Sales Agent as a source
of financing. Because there is no minimum offering amount required as a condition to close this offering, the net proceeds to us, if any,
are not determinable at this time.

We intend to use the net proceeds of this offering,
if any, for general corporate purposes, which may include, without limitation, investing in or acquiring companies that are synergistic
with or complementary to our business and working capital. The amounts and timing of these expenditures will depend on numerous factors,
including the development of our current business initiatives. We have no specific acquisition contemplated at this time. Pending use
of the net proceeds, we intend to invest the net proceeds in short-term, interest-bearing, investment-grade securities or in cash or money
market funds.

<div align='center'>S-8

DILUTION</div>

If you invest in our common stock, your ownership
interest will be diluted to the extent of the difference between the public offering price per share and the as-adjusted net tangible